TransMedics Group, Inc. $TMDX Shares Purchased by Osaic Holdings Inc.

Osaic Holdings Inc. raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 48.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,116 shares of the company’s stock after acquiring an additional 6,899 shares during the quarter. Osaic Holdings Inc. owned approximately 0.06% of TransMedics Group worth $2,830,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in TMDX. Opal Wealth Advisors LLC purchased a new position in shares of TransMedics Group during the second quarter worth about $26,000. Sound Income Strategies LLC acquired a new position in TransMedics Group during the second quarter worth approximately $48,000. Elevation Point Wealth Partners LLC purchased a new stake in TransMedics Group in the second quarter valued at approximately $48,000. Smartleaf Asset Management LLC boosted its holdings in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after acquiring an additional 135 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in shares of TransMedics Group by 72.0% during the second quarter. EverSource Wealth Advisors LLC now owns 485 shares of the company’s stock worth $65,000 after acquiring an additional 203 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Down 2.2%

Shares of TMDX stock opened at $124.20 on Friday. The business’s fifty day moving average price is $129.07 and its 200 day moving average price is $122.74. The firm has a market capitalization of $4.24 billion, a PE ratio of 50.28 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.37 by $0.29. The company had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.12 EPS. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on TMDX. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Evercore ISI initiated coverage on TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price target on the stock. Stifel Nicolaus began coverage on TransMedics Group in a research report on Thursday, September 4th. They set a “hold” rating and a $115.00 price objective for the company. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Finally, Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

Insider Activity at TransMedics Group

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,062 shares of company stock worth $1,797,634 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.